NASDAQ:AIMTAimmune Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aimmune Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.65 -0.34 (-2.43 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$13.57Now: $13.65▼$14.0150-Day Range$13.21MA: $15.34▼$17.6252-Week Range$10.09Now: $13.65▼$37.00Volume671,069 shsAverage Volume1.42 million shsMarket Capitalization$893.39 millionP/E RatioN/ADividend YieldN/ABeta0.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.45, Aimmune Therapeutics has a potential upside of 174.4% from its current price of $13.65.Amount of Analyst CoverageAimmune Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesAimmune Therapeutics has received 466 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAimmune Therapeutics has received 321 “underperform” votes. (Add your “underperform” vote.)Community SentimentAimmune Therapeutics has received 59.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote “Outperform” if you believe AIMT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAimmune Therapeutics does not currently pay a dividend.Dividend GrowthAimmune Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.75% of the stock of Aimmune Therapeutics is held by insiders.Percentage Held by Institutions72.43% of the stock of Aimmune Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aimmune Therapeutics are expected to grow in the coming year, from ($4.44) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aimmune Therapeutics is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aimmune Therapeutics is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAimmune Therapeutics has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220Debt Debt-to-Equity Ratio0.78 Current Ratio7.53 Quick Ratio7.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book4.96Profitability EPS (Most Recent Fiscal Year)($3.97) Net Income$-248,500,000.00 Net MarginsN/A Return on Equity-164.99% Return on Assets-89.50%Miscellaneous Employees228 Outstanding Shares65,450,000Market Cap$893.39 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $13.65 -0.34 (-2.43 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions How has Aimmune Therapeutics' stock price been impacted by COVID-19 (Coronavirus)? Aimmune Therapeutics' stock was trading at $17.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AIMT stock has decreased by 22.3% and is now trading at $13.65. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aimmune Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aimmune Therapeutics. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Aimmune Therapeutics. How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) released its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($1.06). View Aimmune Therapeutics' earnings history. What price target have analysts set for AIMT? 10 Wall Street analysts have issued 12-month price targets for Aimmune Therapeutics' shares. Their forecasts range from $15.00 to $66.00. On average, they expect Aimmune Therapeutics' share price to reach $37.45 in the next year. This suggests a possible upside of 174.4% from the stock's current price. View analysts' price targets for Aimmune Therapeutics. Has Aimmune Therapeutics been receiving favorable news coverage? News articles about AIMT stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aimmune Therapeutics earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the near future. View the latest news about Aimmune Therapeutics. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Reata Pharmaceuticals (RETA), BridgeBio Pharma (BBIO), GW Pharmaceuticals PLC- (GWPH), PTC Therapeutics (PTCT), Opko Health (OPK), Insmed (INSM), Axsome Therapeutics (AXSM), Alkermes (ALKS), Agios Pharmaceuticals (AGIO), Principia Biopharma (PRNB), CytoDyn (CYDY), SAGE Therapeutics (SAGE), Amarin (AMRN), Deciphera Pharmaceuticals (DCPH) and Pacira Biosciences (PCRX). View all competitors. What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Square (SQ) and Roku (ROKU). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the following people: Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Stephen George Dilly, Special Advisor (Age 59)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.42%), FMR LLC (3.52%), Victory Capital Management Inc. (3.16%), Point72 Asset Management L.P. (1.18%), Hudson Bay Capital Management LP (1.02%) and Bank of America Corp DE (1.01%). Company insiders that own Aimmune Therapeutics stock include Andrew Oxtoby, Daniel C Md Adelman, Des Produits Nestle S Societe, Douglas T Sheehy, Eric Bjerkholt, Health Science Us Holdi Nestle, Jayson Donald Alexander Dallas and Patrick G Enright. View institutional ownership trends for Aimmune Therapeutics. Which major investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nantahala Capital Management LLC, FMR LLC, Balyasny Asset Management LLC, Hudson Bay Capital Management LP, GW&K Investment Management LLC, Stifel Financial Corp, and Emerald Advisers LLC. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, and Douglas T Sheehy. View insider buying and selling activity for Aimmune Therapeutics. Which major investors are buying Aimmune Therapeutics stock? AIMT stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Sanders Morris Harris LLC, Victory Capital Management Inc., SG Americas Securities LLC, Rhenman & Partners Asset Management AB, Asymmetry Capital Management L.P., Marshall Wace North America L.P., and Vanguard Group Inc.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Andrew Oxtoby, Des Produits Nestle S Societe, Eric Bjerkholt, Health Science Us Holdi Nestle, Jayson Donald Alexander Dallas, and Patrick G Enright. View insider buying and selling activity for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $13.65. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $893.39 million. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is www.aimmune.com. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
